Physician profile
Misty Sharp Ingram
NPI 1437774080
$557.72
in general payments reported to CMS, 2019-2025
14 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.79 · 2024: $320 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $76.69 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $66.36 | 2024-2025 | Trelegy Ellipta |
| Abbvie INC. | $64.07 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.03 | 2024-2025 | Caplyta |
| Dexcom, INC. | $47.91 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $47.37 | 2024 | Rexulti |
| Exact Sciences Corporation | $42.69 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $40.39 | 2024-2025 | Mounjaro |
| Astellas Pharma US INC | $32.29 | 2024 | Veozah |
| Novo Nordisk INC | $25.18 | 2024 | |
| Vanda Pharmaceuticals INC. | $23.44 | 2025 | Fanapt |
| Verona Pharma, INC. | $14.97 | 2025 | Ohtuvayre |
| Galt Pharmaceuticals, LLC | $13.79 | 2023 | Orphengesic Forte |
| Lundbeck LLC | $13.54 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.